

2021 年度

学会発表(国内学会)

2021.05 第 43 回日本癌局所療法研究会

1. 胃切除不能胃癌に対してSP療法後に conversion surgery を施行し、長期生存が得られた 1 例
高城伸平, 民上真也, 天野優希, 亀井奈津子, 嶋田仁, 榎本武治, 伊澤直樹, 津田亨志, 砂川優, 有泉泰, 大坪毅人.

2021.05 第 62 回日本神経学会学術大会

1. 免疫チェックポイント阻害薬による中枢神経領域の免疫関連有害事象に関する検討.
鎬木真弓, 水上平祐, 松本博文, 菱田吉明, 清水紗智, 緒方聖友, 韓蔚, 井澤直樹, 砂川優, 白石眞, 山野嘉久.

2021.05 第 6 回日本がんサポーターティブケア学会学術集会

1. The Implication of Neurofilament light chain and Galectin-3 in paclitaxel-induced peripheral neurotoxicity for patients with advanced gastric cancer.
Hiroyuki Takeda, Shigenori Kadowaki, Takeshi Kajiwara, Keiko Minashi, Naoki Izawa, Kei Muro, Tomohiro Nishina, Shuichi Hironaka, Takeharu Yamanaka, Takako Eguchi Nakajima.
2. 免疫チェックポイント阻害薬の免疫関連有害事象に対する治療前の抗体検査の意義.
大貫理沙, 伊澤直樹, 濱地広毅, 塩川尚恵, 森川慶, 佐治久, 大橋洋之, 春日井滋, 早川望, 大原樹, 水上拓郎, 田中 恒明, 砂川優.

2021.06 第 27 回日本遺伝性腫瘍学会学術集会

1. 当院におけるがん遺伝子パネル検査の二次的所見に関する検討.
本吉愛, 右田王介, 小澤南, 高橋由妃, 杉下陽堂, 久我亜沙美, 大原樹, 古屋直樹, 小島康幸, 大橋洋之, 山本博幸, 井本清美, 砂川優, 山野嘉久, 津川浩一郎.

2021.09 第 80 回日本癌学会学術総会

1. 胃癌における腸内細菌ゲノム情報と患者背景の関係: DELIVER 試験.
砂川 優, 的場 亮, 佐藤 慶治, 川上 尚人, 室 圭, 中島 貴子, 市川 度.

2021.09 第 52 回日本膵臓学会大会

1. 進行膵癌におけるリキッドバイオプシーと、KRAS 野生型膵癌の治療開発に関する取り組み.
梅本久美子, 森実千種, 中村能章, 池田公史.
2. Efficacy and safety of zenocutuzumab in advanced pancreatic cancer and other solid tumors harboring NRG1 fusions.
Kumiko Umemoto, Ernesto Wasserman.

2021.10 第 59 回日本癌治療学会学術集会

1. がん遺伝子パネル検査に基づいた治療提案と治療到達性.

井本清美, 砂川 優, 武田弘幸, 大原 樹, 小島康幸, 古屋直樹, 大橋洋之, 山本博幸, 小池淳樹, 大川 千絵, 島田 直樹, 本吉 愛, 佐藤知雄, 谷嶋成樹, 山野嘉久.

2. Genomic factors of gut microbiome associated with patient characteristics in gastric cancer: from the DELIVER trial (JACCRO GC-08).

Yu Sunakawa, Ryo Matoba, Yoshiharu Sato, Toshizo Takayama, Takeharu Imai, Naotoshi Sugimoto, Kou Miura, Satoshi Yuki, Yoshiaki Shindo, Hisato Kawakami, Kei Muro, Takako Eguchi Nakajima, Wataru Ichikawa, and Masashi Fujii.

2021.11 第 62 回日本肺癌学会学術集会

1. Efficacy and safety of zenocutuzumab in advanced pancreatic cancer and other solid tumors harboring NRG1 fusions.

Alison M. Schram, Eileen Mary O' Reilly, Grainne M. O' Kane, Koichi Goto, Dong-Wan Kim, Cindy Neuzillet, Patricia Martin-Romano, Michaël Duruisseaux, Misako Nagasaka, Jordi Rodon, Benjamin Adam Weinberg, Kumiko Umemoto, Sai-Hong Ignatius Ou, Teresa Macarulla, Christelle De La Fouchardiere, Andrew K. Joe, Ernesto Wasserman, Viktoriya Stalbovskaya, Jim Ford, Alexander E. Drilon.

2021.11 厚生労働省「治療と仕事の両立支援」オンラインシンポジウム

1. 聖マリアンナ医科大学病院における両立支援相談体制の構築と進捗. 厚生労働省「治療と仕事の両立支援」オンラインシンポジウム

山野嘉久, 長谷川大輔, 萩原悠太, 山徳雅人, 桑島則夫, 杉浦貴子, 伊澤直樹, 梶ヶ谷和子, 高田礼子.

2022.02 第 19 回日本臨床腫瘍学会学術集会

1. 聖遠隔医療を用いた治験プレスクリーニング検査の実装

梅本久美子, 砂川優, 岩見さゆり, 小林奈穂, 松本生, 斉藤修平, 原聖吾.

2. Evaluation of annotations for cancer gene panel testing using a genome-guided system.

Yu Sunakawa, Peter Koch, Hiroyuki Yamamoto, Ai Motoyoshi, Kiyomi Imoto, Martin Maerz, and Yoshihisa Yamano.

3. Symptom monitoring and its digitalization at daily cancer chemotherapy in Japan: a nation-wide multi-stakeholder survey.

Horie Yoshiki, Miyaji Tempei, Kawaguchi Takashi, Kaneyasu Takako, Nagashima Fumio, Doi Ayako, Uneno Yu, Ogura Takashi, Yamaguchi Takuhiro, Nakajima Takako.

4. FOLFOXIRI plus cetuximab versus bevacizumab in RAS wild-type mCRC: the subgroup-analysis of DEEPER trial (JACCRO CC-13).

藪野 太一, 辻 晃仁, 徳永 卓哉, 結城 敏志, 工藤 敏啓, 間下 直樹, 安藤 幸滋, 竹内 信道, 柏田 知美, 片岡 政人, 東風 貢, 佐川 保, 小高 雅人, 久保田 祐太郎, 砂川 優, 関川 高志, 中村 将人, 竹内 正弘, 市川 度, 藤井 雅志.

5. 抗 EGFR 抗体薬併用化学療法に不応/不耐となった進行再発大腸癌患者に対する 2 次治療: FOLFIRI/ラムシルマブ併用療法の第 II 相試験: JACCRO CC-16.
佐川 保, 辻 晃仁, 佐竹 悠良, 中村 将人, 砂川 優, 是久 翔太郎, 松浦 正徒, 湯浅 康弘, 峯 孝志, 永野 浩昭, 重安 邦俊, 金城 達也, 小高 雅人, 奥山 浩之, 久保田 祐太郎, 東風 貢, 舛石 俊樹, 竹内 正弘, 市川 度, 藤井 雅志.
6. Exploratory analysis of baseline tumor burden in the TRUSTY study: Phase 2/3 study of 2nd-line FTD/TPI + BEV for mCRC.
中村 将人, 久保木 恭利, 寺澤 哲志, 舛石 俊樹, 渡邊 純, 尾嶋 仁, 牧山 明資, 小高 雅人, 原 浩樹, 太田 高志, 沖 英次, 砂川 優, 石原 聡一郎, 谷口 浩也, 中島 貴子, 森田 智視, 白尾 國昭, 吉野 孝之.
7. Observational study to evaluate RAS status in ctDNA for mCRC patients with RAS mutant tumor: RASMEX study (JACCRO CC-17).
伊澤 直樹, 賀川 義規, 佐竹 悠良, 砂川 優, 竹内 正弘, 市川 度, 藤井 雅志.
8. Somatostatin receptor: a potential new therapeutic target for primary mucinous neoplasm of the appendix.
水上 拓郎, 新井 裕之, 武田 弘幸, 土井 綾子, 堀江 良樹, 梅本 久美子, 伊澤 直樹, 砂川 優.
9. 切除不能進行結腸直腸癌における分子標的治療薬投与前後の血清 VEGF-A, VEGF-D, PlGF の変動: GI-S 国内学会 GREEN CRC Ukit.
結城 敏志, 砂川 優, 谷口 浩也, 坂東 英明, 山崎 健太郎, 仁科 智裕, 太田 高志, 傳田 忠道, 江崎 泰斗, 川上 尚人, 高島 淳生, 加藤 健志, 安藤 幸滋, 森脇 俊和, 佐藤 太郎, 奥川 喜永, 阿部 由紀子, 野村 尚吾, 淺野 千春, 吉野 孝之.

2022.03 第 94 回日本胃癌学会総会

1. A phase II, non-randomized, prospective trial of biweekly nab-paclitaxel in combination with ramucirumab for patients with previously treated advanced gastric or gastro-esophageal junction cancer: B-RAX trial (JACCRO GC-09)
Yoshio Nagahisa, Naoki Izawa, Takashi Mine, Masahiro Goto, Hitoshi Fujii, Yosuke Kito, Ryohei Kawabata, Masato Nakamura, Mizutomo Azuma, Akihito Tsuji, Mitsugu Kochi, Takao Takahashi, Shigenori Kadowaki, Hirofumi Michimae, Yu Sunakawa, Wataru Ichikawa, Masashi Fujii.

学会発表(国際学会)

2021.06 ASCO Annual Meeting

1. Efficacy and safety of zenocutuzumab in advanced pancreatic cancer and other solid tumors harboring NRG1 fusions.
Alison M. Schram, Eileen Mary O' Reilly, Grainne M. O' Kane, Koichi Goto, Dong-Wan Kim, Cindy Neuzillet, Patricia Martin-Romano, Michaël Duruisseaux, Misako Nagasaka, Jordi Rodon, Benjamin Adam Weinberg, Kumiko Umemoto, Sai-Hong Ignatius Ou, Teresa Macarulla, Christelle De La Fouchardiere, Andrew K. Joe, Ernesto Wasserman, Viktoriya Stalbovskaya, Jim Ford, Alexander E. Drilon.

2. Profiling plasma angiogenesis factors after use of biologics in metastatic colorectal cancer (mCRC); Update results from GI-SCREEN CRC Ukit study.
Yu Sunakawa, Satoshi Yuki, Manabu Shiozawa, Toshiki Masuishi, Tomohiro Nishina, Hisateru Yasui, Takashi Ohta, Naoki Takahashi, Hironaga Satake, Akiyoshi Kanazawa, Masahiro Goto, Hideaki Bando, Hiroya Taniguchi, Yoshinaga Okugawa, Kentaro Yamazaki, Hiromichi Ebi, Yukiko Abe, Shogo Nomura, Chiharu Asano, Takayuki Yoshino.
3. The randomized phase II study of FOLFOXIRI plus cetuximab versus FOLFOXIRI plus bevacizumab as the first-line treatment in metastatic colorectal cancer with RAS wild-type tumors: The DEEPER trial (JACCRO CC-13).
Hisatsugu Otori, Tatsuro Yamaguchi, Masato Matsuura, Atsujiro Nishioka, Akitaka Makiyama, Shingo Noura, Mitsugu Kochi, Tamotsu Sagawa, Masahito Kotaka, Yutaro Kubota, Yu Sunakawa, Takashi Sekikawa, Masato Nakamura, Masahito Takeuchi, Wataru Ichikawa and Masashi Fujii.
4. Genomic alterations for novel targeted therapies in pancreaticobiliary cancers from real-world data.
Kumiko Umemoto, Hiroyuki Yamamoto, Ritsuko Oikawa, Hiroyuki Takeda, Ayako Doi, Yoshiki Horie, Takashi Ogura, Takuro Mizukami, Naoki Izawa, Jay A. Moore, Ethan S. Sokol, Yu Sunakawa.

2021.06 MASCC

1. The Implication of Neurofilament light chain and Galectin-3 in paclitaxel-induced peripheral neurotoxicity for patients with advanced gastric cancer.
Hiroyuki Takeda, Shigenori Kadowaki, Takeshi Kajiwara, Keiko Minashi, Naoki Izawa, Kei Muro, Tomohiro Nishina, Shuichi Hironaka, Takeharu Yamanaka, Takako Eguchi Nakajima.

2021.07 ESMO-GI

1. Gut microbiome to predict survival time in advanced gastric cancer treated with nivolumab: the DELIVER trial (JACCRO GC-08).
Yu Sunakawa, Ryo Matoba, Eisuke Inoue, Yasuhiro Sakamoto, Ryohei Kawabata, Atsushi Ishiguro, Yusuke Akamaru, Yosuke Kito, Masazumi Takahashi, Jin Matsuyama, Hiroshi Yabusaki, Akitaka Makiyama, Takahisa Suzuki, Masahiro Tsuda, Hisateru Yasui, Jun Hihara, Atsushi Takeno, Hisato Kawakami, Kei Muro, Takako Eguchi Nakajima, Wataru Ichikawa, and Masashi Fujii.
2. A multicenter phase II trial of trifluridine/thipiracil in combination with cetuximab in RAS wild-type metastatic colorectal cancer patients refractory to prior anti-EGFR antibody: the WJOG8916G trial.
T. Masuishi, N. Izawa, N. Takahashi, H. Shoji, Y. Yamamoto, T. Matsumoto, K. Sugiyama, T. Kajiwara, K. Kawakami, N. Aomatsu, C. Kondoh, H. Kawakami, N. Takegawa, T. Esaki, Y. Narita, H. Hara, Y. Sunakawa, N. Boku, T. Moriwaki, M. Shimokawa, T. Nakajima, K. Muro.
3. Gene alterations in ctDNA related to the resistance mechanism of anti-EGFR antibodies and clinical efficacy outcomes of anti-EGFR antibody rechallenge plus trifluridine/tipiracil in metastatic colorectal cancer patients in WJOG8916G trial.
N. Takahashi, N. Izawa, K. Nishio, T. Masuishi, H. Shoji, Y. Yamamoto, T. Matsumoto, K. Sugiyama, T. Kajiwara, K.

Kawakami, N. Aomatsu, H. Kawakami, T. Esaki, Y. Narita, H. Hara, Y. Horie, N. Boku, T. Moriwaki, K. Miura, M. Shimokawa, TE. Nakajima, K. Muro.

2021.09 ESMO

1. Impact of plasma angiogenesis factors on the efficacy of 2nd-line chemotherapy combined with biologics in metastatic colorectal cancer (mCRC); Early efficacy results from GI-SCREEN CRC Ukit study.
Satoshi Yuki, Hiroya Taniguchi, Toshiki Masuishi, Manabu Shiozawa, Hideaki Bando, Kentaro Yamazaki, Tomohiro Nishina, Hisateru Yasui, Tadamichi Denda, Yu Sunakawa, Hironaga Satake, Kazuhiro Yoshida, Akiyoshi Kanazawa, Eiji Oki, Yoshinaga Okugawa, Hiromichi Ebi, Yukiko Abe, Shogo Nomura, Chiharu Asano, Takayuki Yoshino.
2. Genomic landscape in advanced gastric cancer from real-world data (RWD) of clinical genomic testing.
H. Yamamoto, R. Oikawa, H. Takeda, K. Umemoto, A. Doi, Y. Horie, T. Ogura, T. Mizukami, N. Izawa, J.A. Moore, E. Sokol, Y. Sunakawa.
3. Placebo-controlled, double-blinded phase III study comparing dexamethasone on day 1 with dexamethasone on days 1 to 4, with combined neurokinin-1 receptor antagonist, palonosetron, and olanzapine in patients receiving cisplatin-containing highly emetogenic chemotherapy: SPARED Trial.
K. Shimomur, H. Minatogawa, T. Mashiko, H. Arioka, H. Iihara, M. Sugawara, N.Hida, K. Akiyama, S. Nawata, A. Tsuboya, K. Mishima, N. Izawa, T. Miyaji, K.Honda, Y. Inada, Y. Ohno, C. Katada, H. Morita, T. Yamaguchi, TE. Nakajima.

2022.01 ASCO-GI

1. A phase II, non-randomized, prospective trial of biweekly nab-paclitaxel in combination with ramucirumab for patients with previously treated advanced gastric or gastro-esophageal junction cancer: B-RAX trial (JACCRO GC-09).
Takahisa Suzuki, Naoki Izawa, Ryohei Kawabata, Kazuhiro Nishikawa, Masazumi Takahashi, Masato Nakamura, Atsushi Ishiguro, Hiroo Katsuya, Jun Hihara, Dai Manaka, Yuji Negoro, Mizutomo Azuma, Akihito Tsuji, Mitsugu Kochi, Takao Takahashi, Shigenori Kadowaki, Hirofumi Michimae, Yu Sunakawa, Wataru Ichikawa, Masashi Fujii.
2. An observational study to evaluate RAS mutations in circulating tumor DNA after standard chemotherapies for metastatic colorectal cancer patients with tumors harboring RAS mutation: RASMEX study (JACCRO CC-17).
Naoki Izawa, Yoshinori Kagawa, Hironaga Satake, Yu Sunakawa, Masahiro Takeuchi, Wataru Ichikawa, Masashi Fujii.
3. A multicenter phase 2 trial of ramucirumab plus FOLFIRI as second-line treatment for patients with RAS wild-type metastatic colorectal cancer previously treated with combination chemotherapy with anti-EGFR antibody: JACCRO CC-16.
Masato Nakamura, Akihito Tsuji, Yoshihiro Okita, Toshihiko Matsumoto, Tamotsu Sagawa, Takanori Watanabe, Kozo Kataoka, Dai Manaka, Kazuhiro Shiraishi, Naoya Akazawa, Tatsuya Okuno, Takaya Shimura, Manabu Shiozawa, Shingo Noura, Yu Sunakawa, Yasuki Akiyama, Hirofumi Ota, Masahiro Takeuchi, Wataru Ichikawa, Masashi Fujii.

4. Exploratory analysis of baseline tumor burden in the TRUSTY study: A randomized phase 2/3 study of trifluridine/tipiracil plus bevacizumab versus irinotecan and fluoropyrimidine plus bevacizumab as second-line treatment in patients with metastatic colorectal cancer.
Toshiki Masuishi, Yasutoshi Kuboki, Tetsuji Terazawa, Masato Nakamura, Jun Watanabe, Hitoshi Ojima, Akitaka Makiyama, Masahito Kotaka, Hiroki Hara, Takashi Ohta, Eiji Oki, Yu Sunakawa, Soichiro Ishihara, Hiroya Taniguchi, Takako Eguchi Nakajima, Satoshi Morita, Kuniaki Shirao, Takayuki Yoshino.
5. Host-related biomarkers including gut microbiome to predict toxicities of nivolumab in advanced gastric cancer: DELIVER trial (JACCRO GC-08).
Yu Sunakawa, Ryo Matoba, Toshizo Takayama, Naoki Okumura, Naotoshi Sugimoto, Kou Miura, Satoshi Yuki, Yoshiaki Shindo, Hidekazu Kuramochi, Sho Sato, Takashi Ogura, Shinichi Kinami, Narutoshi Nagao, Shugo Ueda, Eisuke Inoue, Hisato Kawakami, Kei Muro, Takako Eguchi Nakajima, Wataru Ichikawa, Masashi Fujii.
6. Tumor response of FOLFOXIRI plus cetuximab versus bevacizumab in RAS wild-type metastatic colorectal cancer: The subgroup-analysis of DEEPER trial (JACCRO CC-13).
Hironaga Satake, Akihito Tsuji, Chihiro Tanaka, Takao Takahashi, Kunihiko Wakamura, Taichi Yoshida, Kohei Murata, Yoshiaki Shindo, Yasuhide Ishikawa, Ken Konishi, Mitsugu Kochi, Tamotsu Sagawa, Masahito Kotaka, Yutaro Kubota, Yu Sunakawa, Takashi Sekikawa, Masato Nakamura, Masahiro Takeuchi, Wataru Ichikawa, Masashi Fujii.
7. Genomic landscape in small intestine cancer from real-world data (RWD) of clinical genomic testing.
Hiroyuki Takeda, Hiroyuki Yamamoto, Ritsuko Oikawa, Kumiko Umemoto, Ayako Doi, Yoshiki Horie, Takuro Mizukami, Takashi Ogura, Naoki Izawa, Jay A. Moore, Ethan Sokol, Yu Sunakawa.

論文業績(和文)

《原著・総説・解説》

1. 消化器癌: 診断・治療のすべて
 - 化学療法, 44(6): 608-614.
 - 伊澤直樹、砂川優.

論文業績(英文)

《原著・総説》

1. RAn observational study on nutrition status in gastric cancer patients receiving ramucirumab plus taxane: BALAST study.
 - Future Oncology, 17(19):2431-2438, 2021.
 - Takuro Mizukami, Tempei Miyaji, Yukiya Narita, Tomohiro Matsushima, Takashi Ogura, Hiromichi Miyagaki, Ryohei Kawabata, Yoshiki Horie, Takashi Kawaguchi, Kei Muro, Hiroki Hara, Takuhiro Yamaguchi& Takako E Nakajima.
2. Germ line polymorphisms of genes involved in pluripotency transcription factors predict efficacy of cetuximab in metastatic colorectal cancer.
 - European Journal of Cancer, 150: 133-142, 2021.

- Hiroyuki Arai, Joshua Millstein, Fotios Loupakis, Sebastian Stintzing, Jingyuan Wang, rancesca Battaglin, Natsuko Kawanishi, Priya Jayachandran, Shivani Soni, Wu Zhang, Shannon M Mumenthaler, Chiara Cremolini, Volker Heinemann, Alfredo Falcone, Heinz-Josef Lenz.
3. Circulating Tumor DNA Analysis Detects FGFR2 Amplification and Concurrent Genomic Alterations Associated with FGFR Inhibitor Efficacy in Advanced Gastric Cance.
-
- Clin Cancer Res, 27(20):5619–5627, 2021.
 - Tomoko Jogo, Yoshiaki Nakamura, Kohei Shitara, Hideaki Bando, Hisateru Yasui, Taito Esaki, Tetsuji Terazawa, Taroh Satoh, Eiji Shinozaki, Tomohiro Nishina, Yu Sunakawa, Yoshito Komatsu, Hiroki Hara, Eiji Oki, Nobuhisa Matsuhashi, Takashi Ohta, Takeshi Kato, Koushiro Ohtsubo, Takeshi Kawakami, Naohiro Okano, Yoshiyuki Yamamoto, Takanobu Yamada, Akihito Tsuji, Justin I Odegaard, Hiroya Taniguchi, Toshihiko Doi, Satoshi Fujii, Takayuki Yoshino.
4. Distinct genomic landscapes of gastroesophageal adenocarcinoma depending on PD-L1 expression identify mutations in RAS-MAPK pathway and TP53 as potential predictors of immunotherapy efficacy.
-
- Annals of Oncology, 32(7):906–916, 2021.
 - J Y Wang, J Xiu, Y Baca, H Arai, F Battaglin, N Kawanishi, S Soni, W Zhang, J Millstein, A F Shields, A Grothey, B A Weinberg, J L Marshall, E Lou, M Khushman, D P S Sohal, M J Hall, M Oberley, D Spetzler, L Shen, W M Korn, H J Lenz.
5. Large-scale analysis of KMT2 mutations defines a distinctive molecular subset with treatment implication in gastric cancer.
-
- Oncogene, 40:4894–4905, 2021.
 - Jingyuan Wang, Joanne Xiu, Yasmine Baca, Francesca Battaglin, Hiroyuki Arai, Natsuko Kawanishi, Shivani Soni, Wu Zhang, Joshua Millstein, Bodour Salhia, Richard M Goldberg, Philip A Philip, Andreas Seeber, Jimmy J Hwang, Anthony F Shields, John L Marshall, Igor Astsaturov, A Craig Lockhart, Zoran Gatalica, W Michael Korn, Heinz-Josef Lenz.
6. Real-world effectiveness of nivolumab in advanced gastric cancer: the DELIVER trial (JACCRO GC-08).
-
- Gastric Cancer, 25(1):235–244, 2021.
 - Yoshikazu Takahashi, Yu Sunakawa, Eisuke Inoue, Ryohei Kawabata, Atsushi Ishiguro, Yosuke Kito, Yusuke Akamaru, Masazumi Takahashi, Hiroshi Yabusaki, Jin Matsuyama, Akitaka Makiyama, Masahiro Tsuda, Takahisa Suzuki, Hisateru Yasui, Ryo Matoba, Hisato Kawakami, Takako Eguchi Nakajima, Kei Muro, Wataru Ichikawa, Masashi Fujii.
7. Homologous Recombination Deficiency Alterations in Colorectal Cancer: Clinical, Molecular, and Prognostic Implications.
-
- J Natl Cancer Inst, 114(2):271–279, 2021.
 - Roberto Moretto, Andrew Elliott, Jian Zhang, Hiroyuki Arai, Marco Maria Germani, Veronica Conca, Joanne Xiu, Phillip Stafford, Matthew Oberley, Jim Abraham, David Spetzler, Daniele Rossini, Carlotta Antoniotti, John Marshall, Anthony Shields, Gilberto Lopes, Sara Lonardi, Filippo Pietrantonio, Gianluca Tomasello, Alessandro

Passardi, Emiliano Tamburini, Daniele Santini, Giuseppe Aprile, Gianluca Masi, Alfredo Falcone, Heinz-Josef Lenz, Michael Korn, Chiara Cremolini.

8. Clinical Significance of Circulating Tumor Cell Induced Epithelial–Mesenchymal Transition in Patients with Metastatic Colorectal Cancer by Single–Cell RNA–Sequencing.

 - Cancers (Basel), 13(19):4862, 2021.
 - Masahiro Kozuka, Francesca Battaglin, Priya Jayachandran, Jingyuan Wang, Hiroyuki Arai, Shivani Soni, Wu Zhang, Mitsuharu Hirai, Satoshi Matsusaka, Heinz-Josef Lenz.
9. Clinical implications of using both fluoropyrimidine and paclitaxel in patients with severe peritoneal metastasis of gastric cancer: A post hoc study of JCOG1108/WJOG7312G.

 - Cancer Medicine, 10(21):7673–7682, 2021.
 - Hiroyuki Arai, Eisuke Inoue, Kensei Yamaguchi, Narikazu Boku, Hiroki Hara, Tomohiro Nishina, Masahiro Tsuda, Kohei Shitara, Katsunori Shinozaki, Shinichiro Nakamura, Ichinosuke Hyodo, Kei Muro, Mitsuru Sasako, Masanori Terashima, Takako E Nakajima.
10. Germline polymorphisms in genes maintaining the replication fork predict the efficacy of oxaliplatin and irinotecan in patients with metastatic colorectal cancer.

 - Br J Cancer.126:72–78, 2021.
 - Hiroyuki Arai, Yi Xiao, Joshua Millstein, Jingyuan Wang, Francesca Battaglin, Natsuko Kawanishi, Priya Jayachandran, Shivani Soni, Wu Zhang, Christoph Mancao, Bodour Salhia, Shannon M Mumenthaler, Aparna R Parikh, Heinz-Josef Lenz.
11. Role of nutritional care and general guidance for patients with advanced or metastatic gastric cancer.

 - Future Oncology, 17(23):3101–3109, 2021.
 - Takuro Mizukami, Yongzhe Piao.
12. The potential targeted drugs for fusion genes including NRG1 in pancreatic cancer.

 - Critical Reviews in Oncology/Hematology, 166: 103465, 2021.
 - Kumiko Umemoto, Yu Sunakawa.
13. Second–line chemotherapy after early disease progression during first–line chemotherapy containing bevacizumab for patients with metastatic colorectal cancer.

 - BMC Cancer, 21(1): 1159, 2021.
 - Yamamoto S, Nagashima K, Kawakami T, Mitani S, Komoda M, Tsuji Y, Izawa N, Kawakami K, Yamamoto Y, Makiyama A, Yamazaki K, Masuishi T, Esaki T, Nakajima TE, Okuda H, Moriwaki T, Boku N.
14. Molecular characteristics and clinical outcomes of patients with Neurofibromin 1–altered metastatic colorectal cancer.

 - Springer Nature, 41: 260–267, 2021.
 - Hiroyuki Arai, Andrew Elliott, Joshua Millstein, Joanne Xiu, Fang–Shu Ou, Federico Innocenti, Jingyuan Wang, Francesca Battaglin, Priya Jayachandran, Natsuko Kawanishi, Shivani Soni, Wu Zhang, Davendra Sohal, Richard

M Goldberg, Michael J Hall, Aaron J Scott, Mohd Khushman, Jimmy J Hwang, Emil Lou, Benjamin A Weinberg, Albert Craig Lockhart, Anthony Frank Shields, Jim P Abraham, Daniel Magee, Phillip Stafford, Jian Zhang, Alan P Venook, W Michael Korn, Heinz-Josef Lenz.

15. Clinical Validity of Plasma-Based Genotyping for Microsatellite Instability Assessment in Advanced GI Cancers: SCRUM-Japan GOZILA Substudy.

- JCO Precis Oncol, e2100383, 2022.
- Nakamura Y, Okamoto W, Denda T, Nishina T, Komatsu Y, Yuki S, Yasui H, Esaki T, Sunakawa Y, Ueno M, Shinozaki E, Matsuhashi N, Ohta T, Kato K, Ohtsubo K, Bando H, Hara H, Satoh T, Yamazaki K, Yamamoto Y, Okano N, Terazawa T, Kato T, Oki E, Tsuji A, Horita Y, Hamamoto Y, Kawazoe A, Nakajima H, Nomura S, Mitani R, Yuasa M, Akagi K, Yoshino T.

16. The clinical utility of comprehensive measurement of autoimmune disease-related antibodies in patients with advanced solid tumors receiving immune checkpoint inhibitors: a retrospective study.

- ESMO Open, 7(2):100415, 2022.
- N Izawa, H Shiokawa, R Onuki, K Hamaji, K Morikawa, H Saji, H Ohashi, S Kasugai, N Hayakawa, T Ohara, Y Sunakawa.

17. A phase II multicenter trial assessing the efficacy and safety of first-line S-1 + ramucirumab in elderly patients with advanced/recurrent gastric cancer: KSCC1701.

- Eur J Cancer, 166:279-286, 2022.
- Kazuma Kobayashi, Koichi Suyama, Hiroo Katsuya, Naoki Izawa, Yoshikazu Uenosono, Qingjiang Hu, Tetsuya Kusumoto, Hajime Otsu, Hiroyuki Orita, Hirofumi Kawanaka, Kazunori Shibao, Satoshi Koga, Mototsugu Shimokawa, Akitaka Makiyama, Hiroshi Saeki, Eiji Oki, Hideo Baba, Masaki Mori.

18. Clinical Utility of Genomic Profiling Tests in Patients with Advanced Gastrointestinal Cancers.

- Targeted Oncology, 17:177-185, 2022.
- Hiroyuki Takeda, Kiyomi Imoto, Kumiko Umemoto, Ayako Doi, Hiroyuki Arai, Yoshiki Horie, Takuro Mizukami, Tomoyo Oguri, Takashi Ogura, Naoki Izawa, Hiroyuki Yamamoto, Yoshihisa Yamano & Yu Sunakawa.

19. Impact of Body Weight Loss on Survival in Patients with Advanced Gastric Cancer Receiving Second-Line Treatment.

- Nutr Cancer, 74(2):539-545, 2022.
- Mizukami T, Hamaji K, Onuki R, Yokomizo A, Nagashima Y, Takeda H, Umemoto K, Doi A, Arai H, Hirakawa M, Horie Y, Izawa N, Ogura T, Tsuda T, Sunakawa Y, Shibata M, Tanaka T, Mikami S, Nakajima TE.

《症例報告》

1. Detection of a pinhole-sized bronchoesophageal fistula under bronchoscopic autofluorescence imaging.

- Thoracic Cancer, 12(13):2043-2045, 2021.
- Kei Morikawa, Naoki Izawa, Hirotaka Kida, Hiroshi Handa, Takeo Inoue, Masamichi Ineshita.

2. REMARRY and PURSUIT trials: liquid biopsy-guided rechallenge with anti-epidermal growth factor receptor (EGFR) therapy with panitumumab plus irinotecan for patients with plasma RAS wild-type metastatic colorectal cancer.
 - BMC Cancer, 21(1):674, 2021.
 - Nakajima H, Kotani D, Bando H, Kato T, Oki E, Shinozaki E, Sunakawa Y, Yamazaki K, Yuki S, Nakamura Y, Yamanaka T, Yoshino T, Ohta T, Taniguchi H, Kagawa Y.